Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CannAmide + MEAI
- Development stage
- Preclinical
- Lead developer
- SciSparc
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CannAmide + MEAI is a proprietary combination therapy being developed through a collaboration between SciSparc Ltd. and Clearmind Medicine Inc. The treatment consists of CannAmide™, a formulation of the anti-inflammatory fatty acid amide palmitoylethanolamide (PEA), and MEAI (5-methoxy-2-aminoindane), a non-hallucinogenic psychedelic molecule. This combination is designed to leverage the synergistic effects of its components to address complex conditions such as alcohol use disorder, cocaine addiction, obesity, and depression. Preclinical studies have demonstrated that the combination can effectively reduce alcohol consumption, suppress drug cravings, and promote weight loss by increasing energy expenditure and reducing appetite. The therapy is currently in preclinical development, with patent applications filed for various therapeutic uses.
- Other names
- palmitoylethanolamide + 5-methoxy-2-aminoindanePEA + MEAI
02
Targets
PPARA (Peroxisome proliferator-activated receptor alpha)
Beyond the preview
Go deeper on CannAmide + MEAI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CannAmide + MEAI.